Literature DB >> 15047748

Aberrant tetranectin expression in human breast carcinomas as a predictor of survival.

P Obrist1, G Spizzo, C Ensinger, D Fong, T Brunhuber, G Schäfer, M Varga, R Margreiter, A Amberger, G Gastl, M Christiansen.   

Abstract

AIMS: Tetranectin (TN), a plasminogen kringle 4 binding protein, is thought to play a prominent role in the regulation of proteolytic processes via binding to plasminogen. The aim of this study was to evaluate the expression of TN in human breast cancer and adjacent normal breast tissue and to determine the impact of this expression on survival.
METHODS: A retrospective analysis was performed on 189 patients with breast cancer, with a median follow up time of 10.6 years. The expression of TN was assessed in tumour tissue and adjacent normal breast tissue by immunohistochemistry, and the prognostic relevance of its expression in tumour cells was evaluated.
RESULTS: TN was highly expressed in connective tissue fibres surrounding normal breast epithelium, but not in normal epithelial cells. High expression of TN in tumour cells was found in 131 (69%) of the tumour samples. By western blot analysis, no significant difference in the amount and molecular weight of TN was seen between tumour tissue and normal tissue. Strong TN immunoreactivity in tumour tissue was predictive of poor disease free and tumour specific overall survival. By multivariate analysis, high TN expression in cancer cells was an independent prognostic factor for disease free and tumour specific overall survival.
CONCLUSIONS: Our results demonstrate differential TN expression in normal and malignant breast tissue and a prognostic impact of TN protein expression in breast carcinoma tissue. These data suggest a possible role of TN in invasiveness and the metastatic spread of human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047748      PMCID: PMC1770261          DOI: 10.1136/jcp.2003.010058

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  42 in total

1.  Crystallization and molecular-replacement solution of a truncated form of human recombinant tetranectin.

Authors:  B B Nielsen; J S Kastrup; H Rasmussen; J H Graversen; M Etzerodt; H C Thøgersen; I K Larsen
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2000-05

2.  The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer.

Authors:  X Deng; E V Høgdall; C K Høgdall; B Nørgaard-Pedersen; M Jørgensen; H Nielsen; S A Engelholm
Journal:  Gynecol Oncol       Date:  2000-12       Impact factor: 5.482

3.  Mass spectrometric characterisation of post-translational modification and genetic variation in human tetranectin.

Authors:  M Jaquinod; T L Holtet; M Etzerodt; I Clemmensen; H C Thøgersen; P Roepstorff
Journal:  Biol Chem       Date:  1999-11       Impact factor: 3.915

Review 4.  Plasminogen activators, tissue degradation, and cancer.

Authors:  K Danø; P A Andreasen; J Grøndahl-Hansen; P Kristensen; L S Nielsen; L Skriver
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

5.  [Biochemical mechanism for extracellular proteolysis. Tissue destruction and cancer].

Authors:  L Skriver; L S Nielsen; P Kristensen; K Danø
Journal:  Nord Med       Date:  1983

6.  Serum tetranectin and CA125 in endometrial adenocarcinoma.

Authors:  M S Lundstrøm; C K Høgdall; A L Nielsen; H C Nyholm
Journal:  Anticancer Res       Date:  2000 Sep-Oct       Impact factor: 2.480

7.  Tetranectin expression in gastric adenocarcinomas.

Authors:  D L Arvanitis; E F Kamper; L Kopeikina; A Stavridou; M N Sgantzos; V Kallioras; E Athanasiou; P Kanavaros
Journal:  Histol Histopathol       Date:  2002-04       Impact factor: 2.303

8.  Mice with a targeted deletion of the tetranectin gene exhibit a spinal deformity.

Authors:  K Iba; M E Durkin; L Johnsen; E Hunziker; K Damgaard-Pedersen; H Zhang; E Engvall; R Albrechtsen; U M Wewer
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

9.  The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer.

Authors:  C K Høgdall; L Christensen; I Clemmensen
Journal:  Cancer       Date:  1993-10-15       Impact factor: 6.860

10.  Human breast carcinoma: fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction.

Authors:  H F Dvorak; G R Dickersin; A M Dvorak; E J Manseau; K Pyne
Journal:  J Natl Cancer Inst       Date:  1981-08       Impact factor: 13.506

View more
  15 in total

1.  Cancer-associated fibroblasts promote colorectal cancer progression by secreting CLEC3B.

Authors:  Hui-Fang Zhu; Xu-Hui Zhang; Chuan-Sha Gu; Yan Zhong; Ting Long; Yi-Dan Ma; Zhi-Yan Hu; Zu-Guo Li; Xiao-Yan Wang
Journal:  Cancer Biol Ther       Date:  2019-03-20       Impact factor: 4.742

2.  The cartilage-specific lectin C-type lectin domain family 3 member A (CLEC3A) enhances tissue plasminogen activator-mediated plasminogen activation.

Authors:  Daniela Lau; Dzemal Elezagic; Gabriele Hermes; Matthias Mörgelin; Alexander P Wohl; Manuel Koch; Ursula Hartmann; Stefan Höllriegl; Raimund Wagener; Mats Paulsson; Thomas Streichert; Andreas R Klatt
Journal:  J Biol Chem       Date:  2017-11-16       Impact factor: 5.157

3.  Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer.

Authors:  A Brunner; C Ensinger; M Christiansen; S Heiss; I Verdorfer; G Mikuz; A Tzankov
Journal:  Virchows Arch       Date:  2007-04-13       Impact factor: 4.064

4.  Proteomics study of serum exosomes in Kawasaki disease patients with coronary artery aneurysms.

Authors:  Xiao-Fei Xie; Hong-Juan Chu; Yu-Fen Xu; Liang Hua; Zhou-Ping Wang; Ping Huang; Hong-Ling Jia; Li Zhang
Journal:  Cardiol J       Date:  2018-04-03       Impact factor: 2.737

5.  Exome-wide Association Study Identifies CLEC3B Missense Variant p.S106G as Being Associated With Extreme Longevity in East Asian Populations.

Authors:  Kumpei Tanisawa; Yasumichi Arai; Nobuyoshi Hirose; Hiroshi Shimokata; Yoshiji Yamada; Hisashi Kawai; Motonaga Kojima; Shuichi Obuchi; Hirohiko Hirano; Hideyo Yoshida; Hiroyuki Suzuki; Yoshinori Fujiwara; Kazushige Ihara; Maki Sugaya; Tomio Arai; Seijiro Mori; Motoji Sawabe; Noriko Sato; Masaaki Muramatsu; Mitsuru Higuchi; Yao-Wen Liu; Qing-Peng Kong; Masashi Tanaka
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-03-01       Impact factor: 6.053

6.  CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.

Authors:  Jian Liu; Zhe Liu; Qun Liu; Lina Li; Xiaona Fan; Tao Wen; Guangyu An
Journal:  Oncol Rep       Date:  2018-07-23       Impact factor: 3.906

7.  A Systematic Investigation of the Malignant Functions and Diagnostic Potential of the Cancer Secretome.

Authors:  Jonathan L Robinson; Amir Feizi; Mathias Uhlén; Jens Nielsen
Journal:  Cell Rep       Date:  2019-03-05       Impact factor: 9.423

8.  Sample prep for proteomics of breast cancer: proteomics and gene ontology reveal dramatic differences in protein solubilization preferences of radioimmunoprecipitation assay and urea lysis buffers.

Authors:  Lambert C M Ngoka
Journal:  Proteome Sci       Date:  2008-10-24       Impact factor: 2.480

9.  High Intratumoral Expression of Tetranectin Associates with Poor Prognosis of Patients with Gastric Cancer after Gastrectomy.

Authors:  Hao Chen; Haojie Li; Junjie Zhao; Peike Peng; Miaomiao Shao; Hao Wu; Xuefei Wang; Ling Chen; Qi Zhang; Yuanyuan Ruan; Fenglin Liu; Yihong Sun
Journal:  J Cancer       Date:  2017-10-09       Impact factor: 4.207

10.  Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients.

Authors:  Hong Peng; Sheng Pan; Yuanqing Yan; Randall E Brand; Gloria M Petersen; Suresh T Chari; Lisa A Lai; Jimmy K Eng; Teresa A Brentnall; Ru Chen
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.